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E-mail: dliu2@houstonmethodist.orgChimeric antigen receptor (CAR)-modified T cell therapy has
the potential to improve the overall survival of patients with
malignancies by enhancing the effectiveness of CAR T cells.
Precisely predicting the effectiveness of various CAR T cells
represents one of today’s key unsolved problems in immuno-
therapy. Here, we predict the effectiveness of CAR-modified
cells by evaluating the quality of the CAR-mediated immuno-
logical synapse (IS) by quantitation of F-actin, clustering of
tumor antigen, polarization of lytic granules (LGs), and distri-
bution of key signaling molecules within the IS. Long-term
killing capability, but not secretion of conventional cytokines
or standard 4-hr cytotoxicity, correlates positively with the
quality of the IS in two different CAR T cells that share
identical antigen specificity. Xenograft model data confirm
that the quality of the IS in vitro correlates positively with
performance of CAR-modified immune cells in vivo. Therefore,
we propose that the quality of the IS predicts the effectiveness
of CAR-modified immune cells, which provides a novel strategy
to guide CAR therapy.
INTRODUCTION
Progress using adoptive T cell-based therapy with chimeric antigen
receptors (CARs) shows impressive success in patients with cancer
by enhancing the effectiveness of CAR T cells.1,2 A gap in our
knowledge is an easy way to predict the effectiveness of CAR
T cells. Specifically, many scientists from different laboratories are
generating different CARs with different modifications to optimize
their efficacy. However, these optimized CARs must be evaluated
accurately and cost-effectively for their quality, safety, and potential
effectiveness before they can enter clinical trials. The conventional
tools for immunological analyses of quality and effectiveness are
also time consuming, labor intensive, and costly.
The immunological synapse (IS) was originally described by imaging
T cell interactions with antigen-presenting cells (APCs).3,4 The
structure, function, and signaling cascades at the synapses have
been confirmed by imaging of T cell interactions with the glass-M
This is an open access article under the CC BY-NC-supported planar lipid bilayer containing the major histocompatibil-
ity complex (MHC)-peptide complex and other co-stimulatory
molecules.5–9 The consensus in the field of basic immunology is
that the glass-supported planar lipid bilayer system can be used for
mimicking the target cells to study synapses at high resolution10–12
and can serve as a reductionist approach for studying the IS and its
function.13 Although tremendous progress has been made in basic
immunology research on the IS, with a focus on the structure, func-
tion, and signaling cascades, no study to date has addressed how
the IS of the CAR controls CAR T cell activation and whether CAR
IS quality can predict efficacy in vivo.
Herein, we have applied the glass-supported planar lipid bilayer sys-
tem to study the CAR IS at high resolution. Our images have revealed
several properties of the CAR IS, including both Kappa and CD19
(two distinct tumor antigens), which directly mirror the distribution
of CAR proteins on CAR-modified cells, accumulated at the
CAR-modified immune cell synapse. Multiple parameters, including
the amount of Kappa and CD19, accumulation of F-actin, polariza-
tion of lytic granules (LGs), and distribution of key signaling
molecules at the IS, predicted the effectiveness of the CAR-modified
cells as measured by both tumor cell numbers and CAR-modified cell
proliferation during a long-term killing assay, as well as in vivo effi-
cacy in a mouse xenograft model.
Meanwhile, we developed a novel imaging system to study the
CAR-modified cell’s IS horizontally in a high-throughput manner,
which complements to the glass-supported planar lipid bilayer
system. The vertical cell pairing (VCP) system enables imaging of
the CAR-modified cell’s IS in a horizontal focal plane on botholecular Therapy Vol. 26 No 4 April 2018 ª 2018 The Author(s). 963
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapyfixed- and live-cell imaging.14 This system can also capture more than
3,000 conjugates at a time with high loading efficiency.14 Employing
this VCP system, we presented for the first time a face-to-face look
at the structure and signaling of the IS of the CAR T cells with their
susceptible tumor cells. Moreover, using an in vivo xenograft model,
we demonstrate that the quality of IS predicts in vivo efficacy.
Altogether, we propose that the quality of the IS can predict the
effectiveness of CAR-modified cells, which provides the field of
immunotherapy with a novel strategy to advance the development
of CAR-modified immune cell therapies.
RESULTS
Visualization of CAR T IS by Two Complementary Systems
To test whether CAR T cells can form a stable IS, both Kappa-CAR
and CD19-CARwere stimulated with the glass-supported planar lipid
bilayers carrying fluorescently labeled Kappa and CD19 tumor anti-
gen, respectively. The CAR constructs were described previously.15
The construct is composed of a retroviral vector containing the
single-chain antibody against the CD19 molecule or Kappa chain
protein, the CD28 intracellular domain (hereinafter referred to as
CD28-CAR) or CD28 intracellular domain linked with the cyto-
plasmic domain of 4-1BB (hereinafter referred to as 4-1BB-CAR),
and the zeta chain of the T cell receptor (TCR).15–17 Kappa-
CAR and CD19-CAR share the same intracellular domains (Figures
1A and 1B). The distributions of CAR were imaged by 3-dimensional
(3D) confocal microscopy (Figures 1C and 1D). Images of fixed CAR
T cells on lipid bilayers revealed strong accumulation of Kappa and
CD19 under each CAR T cell, surrounded by F-actin staining, which
is reminiscent of the central cluster of the TCR and B cell receptor
(BCR) at the synapse.3,18
In addition to the structure of the IS, we investigated the intracellular
downstream signaling molecule pZeta (a critical molecule for CAR
signaling), F-actin (an essential component for maintaining the IS
stability19,20), and perforin (a marker for LGs). To visualize the distri-
bution of phosphorylation of the zeta chain, an antibody against the
phosphorylated zeta chain at tyrosine 83 (Y83) was used to stain pZeta
at the IS. As expected, most of pZeta was co-localized with the Kappa
or CD19 antigen, the tumor antigens on the lipid bilayers, which can
directly mirror the distribution of corresponding CAR molecules on
the CAR T cells (Figures 1C and 1D, upper panels). Meanwhile, strong
accumulation of F-actin and polarization of perforin were observed at
the IS (Figures 1C and 1D, upper panels), indicating a functional CAR
IS formation on the glass-supported planar lipid bilayer.
One potential criticism of the glass-supported planar lipid bilayer
system is that it cannot fully mimic the complex surface of a tumor
cell.21 To demonstrate that the IS formation we observed on the
glass-supported planar lipid bilayer can be recapitulated on CAR
T cells with their real susceptible tumor cells, we developed a high-
throughput VCP image device.14 This device allows us to visualize
the IS between the CAR T cell and its susceptible tumor cells in a
vertical focal plane at high resolution. The Daudi cell line positive-
expression Kappa chain was loaded into the VCP device first,964 Molecular Therapy Vol. 26 No 4 April 2018followed by CART cells. Similarly, images of fixed CART cells showed
accumulation of both Kappa andCD19 at the IS. Both F-actin and per-
forinwere polarized at theCART IS (Figures 1C and 1D, lower panels).
Thus, the CAR T cell can form a functional IS, measured by structure,
signaling, and function using two complementary systems.
Superior Quality of IS Formed by 4-1BB-CAR T Cells
Different intracellular domains of CAR can mediate different anti-
tumor activities.22,23 Given the CAR IS formation described earlier
in two CAR T cells, we hypothesize that the quality of the IS (e.g.,
quantitation of its structure, signaling, and function) built by
4-1BB-CAR is different from that of the CD28-CAR T cells.
To test this hypothesis, we quantitatively compared the structure,
signaling, and function of the IS. Stronger F-actin, pZeta, and cen-
tral cluster of tumor antigen staining were observed in 4-1BB-CAR
T cells compared to CD28-CAR T cells derived from the same
donor (Figure 2). Both 4-1BB-CAR T cells and CD28-CAR
T cells can accumulate the Kappa antigen on the lipid bilayers.
Although the distributions of the Kappa clusters in these two
CARs were similar, the mean fluorescence intensity (MFI) of the
Kappa cluster in the 4-1BB-CAR T cells was significantly higher
than that of the CD28-CAR T cells (Figure 2B), indicating superior
anti-tumor activity mediated by 4-1BB co-stimulatory domains.
Quantitative results for Kappa-CAR IS from four other individuals
were summarized (Figure S1). Significantly increased pZeta from
4-1BB-CAR T cells was observed from four of five individuals
(Figure S1). The MFI of F-actin accumulation, kappa antigen clus-
tering, and percentage of LG polarization in 4-1BB-CAR T cells
were significantly higher than those of the CD28-CAR T cells
from four other individuals (Figure S1). Thus, quantitative data
from five individuals suggests that the quality of the IS built by
4-1BB-CAR is superior to that of the CD28-CAR T cells.
To rule out effects of transduction efficiencies and concentrations of
the CARmolecules expressed on the CAR-modified T cells in terms of
the quality of IS, we compared the expression of CAR molecules
among truncated membrane (TM)-only control (Figure 1) and
CD28- and 4-1BB-CAR-modified T cells (Figure S2). The transduc-
tion efficiency (measured by the percentage of CAR molecules) of
CD28-CAR is slightly higher than that of 4-1BB-CAR in both
CD19-CAR- and Kappa-CAR-modified T cells (Figure S2). In addi-
tion to the transduction efficiency, we compared the MFI of CAR
molecules among five individuals, which reflects the number of
CAR molecules per transduced CAR T cell. The quantitative results
from the five individuals showed that the MFI of CAR molecules in
4-1BB-CAR was slightly lower than that in CD28-CAR (Figure S2).
Although the transduction efficiencies and MFI of CD28-CAR are
slightly higher than those of 4-1BB-CAR, the quality of IS
formed by 4-1BB-CAR is superior to the quality of IS formed by
CD28-CAR (Figure 2). Therefore, the differences that we observed
in this study in IS quality between CD28-CAR and 4-1BB-CAR
may not be caused by the transduction efficiencies and expression
of CAR molecules between CD28-CAR and 4-1BB-CAR.
Figure 1. Visualization of the CAR T Cell IS by Two Complementary Systems
(A and B) Schematic representation of recombinant retroviral vectors encoding CAR. Both (A) Kappa- and (B) CD19-CAR constructs (CD28 and 4-1BB) contain the CD28
transmembrane domain and intracellular domain of CD3 zeta, comparing to the TM of Kappa- and CD19-CAR constructs. As a control, these TM controls do not have any
intracellular domain (dash line). (C)Diagramof the lipid bilayer containingAlexaFluor 647-labeled humanKappa IgG1 (left), andconfocal images of theCAR ISon the lipid bilayer
carrying Alexa Fluor 647-labeled human Kappa IgG1 (right). The lower panel shows a schematic model of the VCP system (left) and confocal images of a Kappa-CAR T cell
conjugated with a Kappa chain-positive pre-stained Daudi cell (cyan) (right). (D) Diagram of the lipid bilayer containing Alexa Fluor 568-labeled CD19 (left) and confocal images
of a representative CD19-CAR T cell on the lipid bilayer carrying Alexa Fluor 568-CD19 (right). The lower panel shows a schematic model of the VCP systemwith aCD19-CAR
T cell and its susceptible Raji cell (left) and confocal images of CD19-CAR T cells conjugated with CD19-positive Raji cells (cyan) using the VCP system (right). Fixed and
permeabilized CAR T cells were stained for using antibodies (Abs) against perforin (green), pZeta (cyan), and F-actin (magenta), respectively. Scale bars represent 10.0 mm.
www.moleculartherapy.org
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Figure 2. Quantitative Quality of IS Formed by 4-1BB-CAR and CD28-CAR T Cells
(A) Confocal microscopy of Kappa-4-1BB-CAR T cells and Kappa-CD28-CAR T cells on a lipid bilayer carrying human Kappa IgG1-Alexa Fluor 647 (red). Fixed and
permeabilized CAR T cells were stained for pZeta (cyan) and F-actin (magenta). A visual cartoon of the lipid bilayer and CAR T cells is displayed (left). Scale bars represent
25.0 mm. (B) Quantification of IS on the lipid bilayer-T cell focal plane by measuring the MFIs of F-actin, pZeta, and Kappa cluster on the lipid bilayers containing Kappa IgG1.
Error bars show ±SD. The p value is for unpaired t-test. Data represent three independent experiments.
Molecular TherapyAs a control, CAR T cells were added to the bilayers carrying fluores-
cently labeled lambda immunoglobulin G1 (IgG1) (Figure S3A). No
cells interacted with the lipid bilayer containing lambda IgG1 (Fig-
ure S3A). No clustering in response to lambda IgG1 was observed
for either 4-1BB- or CD28-CAR T cells, which suggests specific inter-
actions and IS formations by CAR T cells on lipid bilayers carrying
their susceptible tumor antigens.
In addition to pZeta (a proximal CAR signaling molecule), we investi-
gated more distal CAR signaling pathways, pZAP-70 (zeta chain-
associated protein 70) and Lck (lymphocyte-specific protein tyrosine
kinase), at the CAR T synapse. As expected, the Kappa IgG1 protein
on the lipid bilayer triggered activities of bothpZAP-70andLck (Figures
S3B and S3C). These two signaling molecules are involved in the long-
term proliferation and differentiation of activated T lymphocytes.24,25
Similar results were obtained from CD19-CAR (Figures S4A and S4B),
which confirms a broad, potential superior effect of 4-1BB co-stimula-966 Molecular Therapy Vol. 26 No 4 April 2018tory domains. Altogether, the data demonstrated superior IS quality
elicited by 4-1BB-CAR T cells compared to CD28-CAR T cells.
Standard 51Cr Release Assay and Cytokine Secretion Cannot
Distinguish the Difference between 4-1BB-CAR- and CD28-
CAR-Modified T Cells
Optimal function of T cells depends on the quality of the IS.26 Given
the superior quality of the IS built by 4-1BB-CAR T cells, we postulate
that 4-1BB-CAR T cells can elicit superior killing activity against their
susceptible tumor cells.
To test this hypothesis, we used the gold standard 4-hr 51Cr release
assay to measure the cytotoxicity of CAR T cells, as well as intracel-
lular cytokine secretion. Upon comparing the cytotoxicity of
4-1BB-CAR T cells and CD28-CAR T cells, we observed that both
4-1BB-CAR T cells and CD28-CAR T cells efficiently killed their
susceptible tumor cells at a different ratio of effector-to-target cells.
The efficiency of the killing ability was dose dependent (Figure 3A).
Figure 3. Neither Standard Killing nor Intracellular
Cytokine and Ratio of CD4/CD8 Can Distinguish the
Difference between 4-1BB-CAR and CD28-CAR
(A) Cytotoxicity of Kappa-CAR T cells (left) and CD19-CAR
T cells (right) from the same healthy donor was measured
using a standard 4-hr 51Cr-release assay. Daudi cells (the
Kappa-positive B cell lymphoma cell line) were used as the
Kappa-CAR T cell’s target cells. Raji cells (the CD19-posi-
tive B cell lymphoma cell line) were used as the CD19-CAR
T cell’s target cells. PBMCs from five individuals were
transduced with 4-1BB construct (red dots) or CD28
construct (black dots) retrovirus. (B and C) Production of
TNF-a and IFN-g by (B) Kappa-CAR and (C) CD19-CAR
from five healthy donors. CAR T cells were stimulated with
target cells for 6 hr in the presence of GolgiStop and bre-
feldin A treatment. The percentages of TNF-a or IFN-g-
positive cells were measured by flow cytometry. (D and E)
Ratio of CD4/CD8 by (D) Kappa-CAR and (E) CD19-CAR
from five individuals. CAR T cell stimulation with corre-
sponding target cells for 6-hr treatment is shown. Surface
staining of CD4- and CD8-positive cells was measured by
flow cytometry. The ratio of CD4/CD8 and CD8 MFI was
calculated by FlowJo software. Error bars show±SD. The p
value is for unpaired t-test.
www.moleculartherapy.orgHowever, both CAR T cells displayed similar anti-tumor activity
against Kappa chain-positive Daudi cells (Figure 3A, left), similar
to CD19-CAR T cells against CD19-positive tumor Raji cells (Fig-
ure 3A, right). We confirmed this observation with multiple target
cell lines to test the 4-hr cytotoxicity of both CD19-CAR and
Kappa-CAR. Similar results were observed under cytotoxicity of
Kappa-CAR T cells against other Kappa-positive cell lines
(JeKo-1 and BJAB17) and cytotoxicity of CD19-CAR T cells against
the Daudi cell line, which expresses CD19 and Kappa chain simul-
taneously from another two individuals (Figure S5). Although
multiple tumor cell lines were used as different target cells, a sig-
nificant difference in 4-hr cytotoxicity between 4-1BB-CAR and
CD28-CAR cannot be detected by a conventional 51Cr release
assay.
In addition to the standard 4-hr cytotoxicity, cytokine production
is an important parameter when evaluating the function of CAR
T cells.27,28 This led us to compare the production of tumor
necrosis factor alpha (TNF-a) and interferon gamma (IFN-g)
between CD28-CAR and 4-1BB-CAR on both Kappa-CAR
and CD19-CAR T cells. The productions of TNF-a and IFN-g
by both Kappa-CAR and CD19-CAR from five individuals
were comparable (Figures 3B and 3C). The ratios of CD4/CD8M
between CD28-CAR and 4-1BB-CAR were
comparable (Figures 3D and 3E, left). The
MFIs of CD8 between CD28-CAR and
4-1BB-CAR was comparable (Figures 3D
and 3E, right). Moreover, interleukin-2
(IL-2) expression is a significant biomarker
for efficient T cell activation.29,30 Thus, intra-cellular IL-2 staining was also examined. No significant difference
in IL-2 expression between CD28-CAR and 4-1BB-CAR was
observed from five individuals (Figure S6).
Overall, we conclude that the 4-hr standard 51Cr release and secretion
of conventional cytokine assays cannot distinguish the difference in
anti-tumor activity between CD28-CAR and 4-1BB-CAR in both
CD19-CAR and Kappa-CAR T cells.
Enhanced Anti-tumor Activity in 4-1BB-CAR T Cells
Previous studies have shown that the anti-tumor activity of CAR
T cells depends on CAR T cell activation, persistence, and prolif-
eration.31 To further examine whether 4-1BB-CAR T cells exhibit
superior anti-tumor activity, we evaluated the persistence and
proliferation of CAR T cells by performing long-term killing assays
(described in Materials and Methods). Specifically, we co-cultured
CAR T cells with their susceptible Daudi cell expressing red fluo-
rescent protein mCherry (Daudi-mCherry) or Raji cell expressing
GFP (Raji-GFP), which can not only measure the eradication of
tumor cells but also monitor the proliferation of CAR T cells.
During a 1-week co-culture period, we quantified both residual
tumor cell numbers (hereinafter referred to as tumor-killing
activity) and expanded CAR T cell numbers (hereinafter referredolecular Therapy Vol. 26 No 4 April 2018 967
Figure 4. Superior Anti-tumor Activity from 4-1BB
CAR T Cells Was Measured by Long-Term Killing
Assay
(A) Diagram of experimental design for long-term killing
assay. (B and C) Anti-tumor effects of Kappa-CAR (B) and
CD19-CAR (C) were measured by the decrease in tumor
cell number (left) and increase in effector cell number
(right). A Kappa-positive Daudi cell expressing fluorescent
protein mCherry was used as a target cell. (B and C) Error
bars show ± SD.
Molecular Therapyto as effector cell proliferation) by flow cytometry (Figure 4A). As
expected, both 4-1BB-CAR T cells and CD28-CAR T cells effi-
ciently eliminated Daudi cells (Figure 4B) or Raji cells (Figure 4C).
4-1BB-CAR T cells eradicated their susceptible tumor cells more
rapidly.
Meanwhile, the proliferation capability of CAR T cells is a critical
parameter for measuring the effectiveness of CAR T cells.16 Longer
persistence of CAR T cells in patients can enhance the effective-
ness of CAR T cells.31 We also measured the proliferation capa-
bility of the CAR T cell by quantifying the CAR T cell numbers
during co-culturing with their susceptible tumor cells. The prolif-
eration capability of 4-1BB CAR T cells derived from different
Kappa-CAR and CD19-CAR specificities increased significantly
compared to that of CD28-CAR T cells and TM-control CAR
T cells (Figure 4B and 4C, right). Similar results from the four
other individuals for Kappa-CAR T cells (Figure S7A) and
CD19-CAR T cells (Figure S7B) were obtained. Quantitative data
from these individuals confirmed the presence of significantly
superior anti-tumor activity in 4-1BB CAR T cells compared to
CD28-CAR T cells (Figure S7).968 Molecular Therapy Vol. 26 No 4 April 2018In summary, the results showed that the 4-1BB
co-stimulatory domains enhanced the anti-tu-
mor activity in vitro through our long-term
killing assay.
Quality of IS Correlates Positively with
Effectiveness of CAR T Cells In Vitro
Given the higher quality of the IS (quantitation
of structure and signaling molecules within the
IS) observed in 4-1BB CAR T cells, we hypoth-
esize that the quality of IS correlates positively
to the effectiveness of CAR T cells, as specu-
lated previously.32 If so, we can predict the
effectiveness of Kappa-CAR T cells and
CD19-CAR T cells by evaluating the quality
of the IS. To test this hypothesis, we used an
accumulation of pZeta and F-actin, cluster of
tumor antigen, and polarization of LG to mea-
sure the quality of the IS, while we measured
the anti-tumor activity of CAR T cells by
long-term killing assays from the same donor.Quantitative data from five individuals showed significantly higher
quality of the IS in 4-1BB-CAR T cells compared to CD28-CAR
T cells (Figure S8).
To quantify the effectiveness of the CAR T cells, we used the recip-
rocal of the area under the curve of tumor cell numbers (hereinafter
referred to as killing efficiency) and the area under the curve of
T cell numbers (hereinafter referred to as proliferation efficiency)
in long-term killing assays (Figure S9). Quantitative data from five
individuals showed significantly higher anti-tumor activity in 4-
1BB-CAR T cells compared to CD28-CAR T cells, as measured
by the reciprocal of the area under the curve of tumor cell numbers
and the area under the curve of T cell numbers in long-term killing
assays (Figure S9).
Then, we performed the correlation analysis between IS quality and
anti-tumor activity. 4-1BB-CAR T cells from the five donors showed
a positive correlation between the quality of the IS and the killing
efficiency (Figure 5A), as well as proliferation efficiency (Figure 5B).
In conclusion, the quality of IS correlates positively with the effective-
ness of CAR T cells in vitro.
Figure 5. Positive Correlation between Anti-tumor
Effects and IS Quality
(A) Correlation analysis between the quality of the IS and
the killing efficiency (the reciprocal of area under the curve
of tumor cell numbers). (B) Correlation analysis between
the quality of the IS and the proliferation efficiency (the area
under the curve of T cell numbers). The quality of the IS
was measured by the intensities of F-actin, pZeta, and
cluster of tumor antigen, as well as the percentage of
perforin polarization. The Pearson r value was calculated.
Each dot represents one donor. These data represent at
least three independent experiments.
www.moleculartherapy.org
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Figure 6. Superior Anti-tumor Activity from 4-1BB- and Kappa-CAR NK-92 Cells in a Lymphoma Xenograft Model
(A) Representative IS quality measured by quantification of Kappa antigenMFI on the glass-supported planar lipid bilayer between CD28-CAR (red) and 4-1BB-CAR (blue). (B)
Diagram of the experimental design of the lymphoma xenograft model. NSG mice (n = 6) were i.v. injected with 1  106 FFLuc-Daudi cells (Day 7). At day 1, mice were
injected (i.v.) with one dose of 1 107 effector CARNK-92 cells (CD28 and 4-1BB) with 2 104 IU of IL-2, and the control group was injected with 2 104 IU of IL-2 in PBS. At
days 4 and 7,micewere injected with CAR-NK-92 cells with IL-2. (C) Representative images of the tumor burden at the indicated time points. The fluorescence intensity range
is displayed (right). (D) Quantification of the tumor burden. Mice were imaged at the indicated days to evaluate the tumor burden expressed as bioluminescence (in photons
per second). (*p < 0.05, **p < 0.01, unpaired two-tailed Student’s t test analysis). Tumor growth was quantified via luciferin signal (average light intensity) and plotted. (E)
Tumor growth inhibition (TGI, as a percentage) was calculated at the indicated time points. (D and E) Error bars show ± SD.
Molecular TherapyQuality of IS Correlates Positively with Effectiveness of CAR NK
Cells In Vivo
To evaluate whether the quality of IS correlates positively with anti-
tumor activity in vivo and determine whether IS can predict in vivo
efficacy, two natural killer (NK) 92 cell lines stably expressing
Kappa-CD28-CAR and Kappa-4-1BB-CAR were established. The ef-
ficiencies of CAR expression in these two NK-92 cell lines were above
95% after flow cytometry analysis (D.L. andW.X., unpublished data).
First, we employed the glass-supported planar lipid bilayer system to
detect the IS formed by Kappa-CAR NK-92 cells. The MFI of the
Kappa cluster in the 4-1BB-CAR NK-92 cells is significantly higher
than that of the CD28-CAR NK-92 cells (Figure 6A). Similar obser-
vations of F-actin accumulation and other parameters at the IS
were obtained (D.L. and W.X., unpublished data).
Furthermore, we compared anti-tumor activities between Kappa-
CD28-CAR and Kappa-4-1BB-CAR using a lymphoma xenograft
model in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG) mice. FireFly
luciferase (FFLuc)-tagged Daudi (FFLuc-Daudi) cells were implanted
by intravenous (i.v.) tail vein injection. Tumor burden was assessed at
indicated points by measuring tumor-derived bioluminescence
followed by CAR-NK-92 infusion (Figure 6B). Mice treated with970 Molecular Therapy Vol. 26 No 4 April 20184-1BB-CAR NK-92 cells show superior anti-tumor activities
compared with mice with CD28-CARNK-92 after treatment (Figures
6C and 6D). Similar results on tumor growth inhibition (TGI) were
obtained (Figure 6E).
To validate this observation, we mimicked a solid tumor xenograft
model by implanting the luciferase-tagged Daudi cell line subcutane-
ously. As expected, mice treated with 4-1BB-CAR NK-92 cells
showed superior anti-tumor activities compared with those treated
with CD28-CAR NK-92 in this solid tumor xenograft model (Fig-
ure S10). Thus, the quality of the IS correlates positively with the
effectiveness of CAR-modified cells.
In conclusion, we propose that the quality of the IS can predict the
effectiveness of CAR-modified immune cells.
DISCUSSION
Cancer immunotherapy has been investigated for more than
126 years, since surgeon Dr. William Coley began treating cancer
patients with bacteria (Streptococcus pyogenes) in 1891.33 Progress
in CAR T cell-mediated immunotherapy delivers the promise of
treating various cancers.34–39 The mechanisms proposed for
www.moleculartherapy.orgexplaining the effectiveness of the CAR T cell focus mainly on the
capabilities of cytokine secretion, cytotoxicity, proliferation, and
homing to the tumor site.40 However, the exact molecular mecha-
nisms at the level of the single cell remain unclear. Specifically, the
IS between CAR-modified cells and susceptible target cells has not
been extensively explored, although the IS has been studied for
more than three decades in the field of basic immunology.3
In this study, we documented detailed information about the CAR IS.
Both CD19-CAR and Kappa-CAR T cells formed a stable IS on the
glass-supported planar lipid bilayer carrying the corresponding
tumor antigens such as CD19 and Kappa molecules, as well as their
susceptible target cells in a newly developed VCP imaging device.14
The quality of the IS can be used to predict the effectiveness of the
CAR-modified cells in vitro and in vivo, which provides a novel
strategy for clinicians to cost-effectively assess the CAR-modified
immune cells.
The commonality between the CAR IS and the TCR-mediated IS is
intriguing. TCR can accumulate at the center of the IS in the presence
of integrin and other co-stimulatory molecules, because classic IS is a
concentric structure of the central region, surrounded by an outer
ring of adhesion molecules (LFA-1/ICAM-1) in the periphery.3,41
In this study, we focused on the CAR molecule only, without other
co-stimulatory molecules (e.g., integrin) on the glass-supported lipid
bilayer system. This allows investigators to determine the influence of
individual receptor and ligand interactions on CAR IS formation.10,13
Similarly, CD19-CAR and Kappa-CAR molecules accumulated at the
CAR IS upon stimulation of the CAR by the corresponding tumor
antigens, surrounded by F-actin (an essential component for main-
taining IS stability and defining the periphery of the synapse42–46).
After accumulation of the surface artificial receptors expressed on
CAR T cells, these CAR microclusters can trigger downstream
signaling cascades. Strong accumulation of key signaling molecules
such as pZeta was observed, which is reminiscent of the accumulation
of proximal TCR signaling molecules,47,48 a hallmark feature of T cell
activation.
Accumulation of F-actin at the IS plays an important role in T cell IS
formation46,49 and was observed at the CAR IS in this study. One of
the critical outcomes of accumulation of F-actin at the IS is the polar-
ization of LG toward target cells.50 Similarly, the polarization of LG
has been observed in activated CAR-modified immune cells in the
two complementary systems (the glass-supported planar lipid bilayer
system and the VCP system) in this study. Both CAR and TCR induce
an F-actin ring at the IS, but F-actin was not completely depleted at
the center of the IS, which is consistent with previous observations
in human NK cells.10,51,52 Therefore, we have demonstrated that
CAR-modified immune cells use a mechanism similar to that of the
cytotoxic lymphocytes for cytotoxicity.
One of the contributions of this study is that we compared the quality
of the IS between CD28-CAR and 4-1BB-CAR. We evaluated the
quality of the IS by quantifying the MFI of tumor antigens on lipidbilayers (structure of the CAR IS), the MFI of key signaling molecules
(signaling cascades at the CAR IS), accumulation of F-actin, and po-
larization of LG (function of the CAR IS). The quality of the IS,
measured by structure, signaling, and function, built by 4-1BB-CAR
is superior to that built by CD28-CAR, which could explain the supe-
rior tumor control from 4-1BB-CAR immunotherapy.53 The superior
IS quality built by 4-1BB-CAR is due to neither the expression level of
CAR molecules on each immune cell nor the transduction efficiency.
Moreover, there are no significant differences in ratio of CD4/CD8
and IL-2 expression between CD28-CAR and 4-1BB-CAR. The trans-
duction efficiencies of CD28-CAR are slightly higher than those of
4-1BB-CAR from five individuals; however, the quality of the IS
formed by 4-1BB-CAR is superior to the quality of that formed by
CD28-CAR.
In vivo persistence and expansion of adoptively transferred CAR-
modified immune cells are crucial to obtain sustained clinical
response.54–56 Precisely predicting and evaluating the quality and
effectiveness of CAR T cells represents a major effect in the field of
immunotherapy. The 4-hr 51Cr release assay is a gold-standard
approach for measuring cytotoxicity of lymphocytes that has been
widely used to evaluate the cytotoxicity of lymphocytes.57 This assay,
however, could not effectively distinguish the difference in effective-
ness between CD28- and 4-1BB-CAR T cells employing both
Kappa-CAR and CD19-CAR in this study.
We propose that the long-term killing assay serves as a superior
method to evaluate the effectiveness and proliferation of CAR-modi-
fied immune cells compared to 4-hr 51Cr release assay. Significant
differences between CD28- and 4-1BB-CAR in both controlling the
numbers of tumor cells and T cell expansion have been observed by
the long-term killing assay (but not the 4-hr standard 51Cr release
assay), which correlates positively with the quality of the stable IS
formed by both CD19-CAR and Kappa-CAR. However, the long-
term killing assay is (1) time consuming, taking 1–2 weeks; (2)
requires the fluorescently labeled tumor cells; (3) does not have the
potential role to perform high-throughput evaluation; and (4) cannot
reach the high-resolution evaluation at the level of a single cell. We
confirmed the anti-tumor activities between Kappa-CD28-CAR and
Kappa-4-1BB-CAR using a lymphoma xenograft model in NSG
mice, which suggests that IS quality in vitro can predict in vivo
CAR-modified immune cell efficacy. However, the differences we
observed at the CAR IS may underscore the importance of both
not generalizing a finding from any single series of receptors and
not comparing side-by-side the receptors generated by different
investigators.58
In this study, we demonstrate that the proposed approach has a num-
ber of distinct advantages. The role of 4-1BB co-stimulation in other
CAR constructs, including CD20-CAR, CD30-CAR, EGFR-CAR, and
GD2-CAR, has not been documented and may be either functionally
beneficial or deleterious for certain CAR constructs.59 No clinical
direct comparisons between 4-1BB-CAR and CD28-CAR efficacy
exist, but phase I and II data suggest similar complete response ratesMolecular Therapy Vol. 26 No 4 April 2018 971
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4-1BB-CAR60 and 88% with CD19-CD28-CAR.61 Therefore, not all
CARs linked to the 4-1BB signaling domain may be superior to those
linked to the CD28 co-stimulatory domain. Investigation to measure
all CARs is beyond the scope of this study, which is designed to
address a significant, unanswered question by developing an
easy-to-use, high-throughput, cost-effective approach to evaluate
the quality of the CAR T IS.
The approach we propose in this study could provide a novel tool to
predict the effectiveness of a CAR T cell by quantifying IS quality,
which may introduce a new parameter to the field of immunotherapy.
At present, no single parameter can predict the efficacy of a CAR
T cell’s clinical outcome. The IS quality could be used in conjunction
with other parameters such as long-term killing assay and other
conventional parameters as a composite clinical predictor. To this
end, the technology and knowledge generated in this study may allow
clinically applicable, high-throughput analysis of these single-cell
high-resolution assays.
In summary, we provide a novel tool to predict the effectiveness
of CAR-modified immune cells, especially the CAR T cell, by
quantifying the quality of the IS. Using IS quality to predict the
efficacy of immunotherapy and side effects of CAR-modified im-
mune cells will introduce a tool or parameter into the field of
immunotherapy.MATERIALS AND METHODS
Cell Lines
The following cell lines were used: Daudi, JeKo-1, BJAB, Raji (CD19+
Burkitt’s lymphoma cell lines), HEK293T, and NK-92. All cell lines
were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA). Daudi and Raji cell lines were main-
tained in RPMI-1640 (Gibco, San Francisco, CA, USA) supplied
with 10% fetal bovine serum (HyClone, Waltham, MA, USA) and
2 mM L-glutamine (Gibco). HEK293T cells were maintained in
DMEM (Gibco) supplied with 10% fetal bovine serum (HyClone)
and 2 mM L-glutamine (Gibco). NK-92 cells were maintained and
passaged according to ATCC official recommendations.Plasmid Construction and Retrovirus Production
The Kappa-CAR and CD19-CAR constructs used in this study were
described previously.15 Both Kappa and CD19 single-chain variable
fragment (scFv) sequences were cloned in a SFG retroviral backbone
in frame with the hinge of the human IgG1 and the z chain of the
human TCR/CD3 complex. All constructs contain a transmembrane
domain of CD28 to ensure equal expression of the CAR constructs.
Retroviral supernatants were produced by transfecting HEK293T
cells with a combination of plasmid containing CD19-specific scFv
or Kappa-specific scFv, RDF plasmid encoding the RD114 envelope,
and PegPam3 plasmid encoding MoMLV gag-pol, as previously
described.15972 Molecular Therapy Vol. 26 No 4 April 2018Generation of CAR-Modified T Cells
Peripheral blood mononuclear cells (PBMCs) were obtained from
healthy donors according to the approved protocols. To transduce
the PBMCs, cells were activated with 1 mg/mL anti-CD3 (clone,
OKT3, Ortho Biotech, Bridgewater, NJ, USA) and 1 mg/mL anti-
CD28 with 100 U/mL recombinant human IL-2 (Proleukin; Chiron,
Emeryville, CA, USA) in 10% fetal bovine serum (FBS) RPMI-1640
media. Activated T cells were transduced with retroviral supernatants
on day 3 in plates coated with recombinant fibronectin fragment
(FN CH-296; Retronectin; Takara Shuzo, Otsu, Japan). After trans-
duction, T cells were expanded using IL-2 and then used for assays.
51Cr Release Assay
To evaluate the cytotoxic activity of CAR T lymphocytes, standard
4-hr 51Cr release assay was used.17 Target cells were labeled with
51Cr at 37C for 1 hr and then re-suspended at 1  105/mL in
RPMI medium with 10% FBS. 1  104 target cells were incubated
with serial-diluted CAR T cells at 37C for 4 hr. After centrifugation,
the supernatants were collected and the released 51Cr was measured
with a gamma counter (Wallac, Turku, Finland). The cytotoxicity
(as a percentage) was calculated as follows: [(sample  spontaneous
release) / (maximum release  spontaneous release)]  100.
Intracellular Cytokine Staining
The CAR T cells were suspended with pre-warmed R10 medium con-
taining brefeldin A (20 mL/mL, Sigma-Aldrich) and GolgiStop
(1.4 mL/mL, BD). The target cells were added into the wells to stimu-
late the CAR T cells for 6 hr in the incubator. After stimulation, the
cells were stained with the viability dye followed by surface staining
with CD3 (Clone OKT3), CD4 (Clone OKT4), and CD8 (Clone
RPA-T8) antibodies (BioLegend, San Diego, CA, USA). After
washing with PBS, the cells were permeabilized with Cytofix/Ctyo-
perm buffer (BD Biosciences) for 20 min at room temperature and
then washed with 1  BD Perm/Wash buffer twice. Next, the cells
were stained with the intracellular antibodies, including TNF-a
(Clone MAb11) and IFN-g (Clone B27; both BioLegend).
Long-Term Killing Assay
To evaluate the long-term anti-tumor activity of CAR T cells, a long-
term killing assay was used.16,17 CART cells were co-cultured with the
Kappa light-chain-positive Daudi cell expressing fluorescent protein
mCherry or CD19+ Raji-GFP with an effector-to-target (E:T) ratio
of 1:2. Specifically, 50,000 target cells and 25,000 CAR T effector
cells were mixed with 10% counting beads (Cat. No. 01-1234-42,
eBioscience) per well and plated into 96-well plates. After the
indicated days of mixture, cells were analyzed by flow
cytometry. The numbers of CAR T cells and target cells were calcu-
lated by the following equation: absolute count (cells per
microliter) = [(cell count  eBead volume) / (eBead count  cell
volume)]  eBead concentration.
Glass-Supported Planar Lipid Bilayer
Planar lipid bilayers were prepared by fusing small liposome droplets
with clean glass coverslips as described.62 The liposome was trapped
www.moleculartherapy.orgin a m-Slide VI 0.4 chamber (Ibidi, Germany). Lipid bilayers were first
blocked with 5% casein for 30 min and then incubated with 6.3 nM
streptavidin (Life Technologies) for 20 min. After being washed
extensively with imaging buffer (HEPES-buffered saline), bilayers
were incubated with biotinylated antibodies conjugated with Alexa
Fluor dyes at room temperature for 30 min. After a second wash
with imaging buffer, bilayers were blocked with 2.5 mM D-biotin to
saturate the streptavidin-binding sites. Cells were activated on the
lipids for 60 min.
Confocal Imaging on the Planar Lipid Bilayer
CAR T cells were stimulated on lipid bilayers containing either
fluorescently labeled Kappa or CD19 proteins. Cells were stained by
fluorescently conjugated antibodies against perforin (deltaG9,
Thermo Scientific), pZeta (phosphor-Y83, Abcam), LCK (3A5, Santa
Cruz), and pZAP-70 (Tyr 319, Cell Signal), as described previously.63
F-actin was stained by Alexa Fluor 532-conjugated phalloidin (Life
Technologies). A Leica TCS SP8 microscope (Leica, Germany) was
used to obtain confocal image data.
Conjugation Experiment on the Device
The VCP device is composed of two polydimethylsiloxane (PDMS)-
layer micropit and microtrap arrays, as described previously.14 Before
seeding the cell, the VCP device was pre-coated with 2% BSA in PBS.
Then, R10mediumwas used to replace the BSA solution in the device.
10 mL of the effector cell suspension with a concentration range of
106–107 cells/mL was added into the inlet. 20 mL of R10 medium
was withdrawn by a 1-mL syringe to generate flow. After 30 s of seed-
ing, the remainder of the cell suspension was washed with medium.
The microfluidic device was centrifuged at 2,000 rpm for 10 min to
spin down the cells into a micropit array. Target cells were stained
with eFluor 450 (65-0842-85, eBioscience) and were added into the
inlet. The parameters for seeding the second cell suspension were
the same as those for the first cell suspension.
For fixed-cell imaging, the device was incubated for 1 hr at 37C to
form a stable IS. The cell-cell conjugates were fixed by 4% formalde-
hyde solution in PBS for 15 min and then washed with PBS for 5 min.
Permeabilization buffer containing 5% of normal donkey serum
(NDS) and 0.5% Triton X-100 in PBS was flowed into the device
for 1 hr. The permeabilization buffer was washed with PBS for
5 min. Next, primary antibodies in buffer containing 3% NDS and
0.5% Triton X-100 in PBS were pumped into the device. The device
was incubated in 4C overnight. The antibody buffer was washed
with PBS for 5 min. Cells were then stained with fluorescently labeled
secondary antibodies for 1 hr at room temperature. The antibody
buffer was washed with PBS for 5 min, and finally, a drop of ProLong
Gold antifade reagent mounting medium (Life Technologies) was
added into the device.
Animal Studies
All animal experiments were approved by the Houston Methodist
Research Institute Institutional Animal Care and Use Committee
(IACUC). Eight-week-old male and female NSG mice (JacksonLaboratory) weighing 18–20 g were used. To establish the in vivo
tumor model, CD19-positive Daudi cells were transduced with the
lentiviral vector encoding FFLuc, as previously described.17 Kappa-
positive cells of FFLuc-Daudi were sorted using a fluorescence-
activated cell sorting (FACS) Aria II cell sorter (BD Biosciences)
by mlgG1 anti-human Kappa (SB81a) biotinylated-Alexa 568 and
were designated as FFLuc-Daudi cells. The NSG mice were i.v.
injected with 1  106 FFLuc-Daudi cells in 150 mL of PBS via
tail vein to establish a human lymphoma xenograft model (n = 6).
Beginning on day 1, the mice were injected (i.v.) with 1  107
CAR-modified effector cells, including CD28-CAR NK-92 and
4-1BB-CAR NK*-92, in 150 mL of PBS at days 1, 4, and 7.
Isoflurane-anesthetized animals were imaged using the IVIS system
(IVIS-200, PerkinElmer, Waltham, MA, USA) 10 min after
150 mg/kg D-luciferin (Gold Biotechnology, St. Louis, MO, USA)
per mouse administered intraperitoneally (i.p.). The photons emitted
from the luciferase-expressing tumor cells were quantified using
Living Image software 64 (Caliper Life Sciences, Hopkinton, MA,
USA). A pseudo-color image representing light intensity (blue least
intense and red most intense) was generated and superimposed
over the grayscale reference image. A constant region of interest
(ROI) was drawn over the whole animal, excluding the tail, and the
intensity of the signal was measured as total photons per second. After
effector NK-92 cell injections, animals were imaged twice or three
times a week for tumor cell tracking at the preclinical imaging
core of the Houston Methodist Research Institute. TGI was
determined as indicated by the formula64 %TGI = (1  [Tt/T0 /
Ct/C0] / 1  [C0/Ct])  100, where Tt is the median tumor volume
of treated at time t, T0 is the median tumor volume of treated at
time 0, Ct is the median tumor volume of control at time t, and C0
is the median tumor volume of control at time 0.
Statistical Analysis
Unpaired or paired two-tailed t tests were performed using the Prism
software (GraphPad Software, La Jolla, CA, USA). The correlation be-
tween quality of IS and anti-tumor activity was analyzed by a linear
regression correlation analysis (GraphPad).
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